Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00814021 | Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain | completed | Phase 2 | 21 | Institut Claudius RegaudOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 |
| clinicaltrials |
| NCT02719613 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | completed | Phase 2 | 67 | Bristol-Myers SquibbINDUSTRY | 13 | Apr 15, 2026 | clinicaltrials |
| NCT04886271 | Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors | completed | Phase 2 | 20 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05304936 | HCW9218 for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 21 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01902680 | Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.(CURIEFOCALE) | completed | Phase 2 | 18 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02866747 | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma(STERIMGLI) | completed | Phase 1 / Phase 2 | 108 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03446547 | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)(ASTEROID) | completed | Phase 2 | 106 | Vastra Gotaland RegionOTHER_GOV | 3 | Apr 14, 2026 | clinicaltrials |
| NCT04704453 | Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.(TEC-ORL) | completed | Phase 2 | 13 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529613 | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma(T-DXd_HER2Low) | completed | Phase 1 / Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02225704 | Radium-223 in Combination With Enzalutamide | completed | Phase 2 | 45 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02630693 | Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer | completed | Phase 2 | 180 | Canadian Cancer Trials GroupNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02772588 | AASUR in High Risk Prostate Cancer | completed | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02928978 | Ruxolitinib for Premalignant Breast Disease(TBCRC042) | completed | Phase 2 | 84 | Julie NangiaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03601806 | Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection | completed | Phase 2 | 26 | AIDS Malignancy ConsortiumNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03259035 | NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer | completed | Phase 2 | 58 | Canadian Cancer Trials GroupNETWORK | 2 | Apr 9, 2026 | clinicaltrials |
| NCT03466294 | Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | completed | Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03523702 | The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial(SPRINT) | completed | Phase 2 | 25 | Montefiore Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04433156 | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma | completed | Phase 2 | 26 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT01241734 | Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL(RICER) | completed | Phase 1 / Phase 2 | 18 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01453101 | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma(Flu-Mel-Vel) | completed | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02405364 | Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction(IFM-CRd) | completed | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02595905 | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | completed | Phase 2 | 344 | National Cancer Institute (NCI)NIH | 2 | Apr 8, 2026 | clinicaltrials |
| NCT04420884 | A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors(iintune-1) | completed | Phase 1 / Phase 2 | 248 | TakedaINDUSTRY | 11 | Apr 8, 2026 | clinicaltrials |
| NCT04660097 | Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer | completed | Phase 2 | 34 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05077709 | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | completed | Phase 2 | 63 | IO BiotechINDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT05694819 | Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) | completed | Phase 2 | 57 | National Cancer Center Hospital EastOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07307911 | Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy(Co-Pa-N) | completed | Phase 2 | 50 | Damanhour UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01679119 | Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy(INCA) | completed | Phase 2 | 129 | University College, LondonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02302495 | Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma(IFM2012-03) | completed | Phase 2 | 32 | University Hospital, LilleOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02626481 | Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma(IFM2014-04) | completed | Phase 2 | 64 | University Hospital, LilleOTHER | 2 | Apr 7, 2026 | clinicaltrials |
| NCT04834674 | DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05563480 | TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 47 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT01067287 | Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | completed | Phase 2 | 35 | Beth Israel Deaconess Medical CenterOTHER | 2 | Apr 6, 2026 | clinicaltrials |
| NCT02087423 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer(ATLANTIC) | completed | Phase 2 | 446 | AstraZenecaINDUSTRY | 18 | Apr 6, 2026 | clinicaltrials |
| NCT02518555 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 42 | Jennifer WoyachOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02816021 | Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03158129 | Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 101 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03459222 | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 229 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 6, 2026 | clinicaltrials |
| NCT04983901 | PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05394285 | A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer | completed | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06238687 | A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT01502085 | Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens(RZD) | completed | Phase 1 / Phase 2 | 25 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT01723839 | Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide(FCR) | completed | Phase 2 | 21 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT01813227 | A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 | completed | Phase 2 | 7 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02077881 | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02204085 | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 33 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 15, 2026source: clinicaltrials